Perspective · 10 Sep 2026
Research articlePublished 2014
Sequential Therapy with Tenofovir Plus Peg Interferon Enhances Innate and Adaptive Immunity Compared to Tenofovir Monotherapy in Chronic Hepatitis B Patients
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Viral load reduction followed by immunomodulation is an emerging approach to improve the treatment outcomes in patients with Chronic Hepatitis B (CHB). Persistent functional defects in Dendritic Cells (DC) have been observed in CHB patients, even with effective antiviral therapy. We investigated the effects of Tenofovir plus Peg-IFN Sequential Therapy (SQT) on functional restoration of innate and adaptive immunity in CHB patients. HBeAg+ve CHB patients were randomized to receive 48weeks of either tenofovir monotherapy (TM; Gr.1, n=30) or tenofovir with addition of PEG interferon from week 12 to 36 followed by tenofovir sequential therapy (SQT; Gr. 2, n=28) for 48 weeks. Biochemical parameters improved significantly with treatment at week 24 in both groups, but HBeAg seroconversion at week 48 occurred more frequently after SQT (21%) than TM (13%). At week 24, the expression and function of TLR7 and TLR9 in DCs were significantly increased in SQT compared to TM (p<0.05). Phagocytic activity of DCs, production of IFN-α and TNF-α by mDCs and pDCs and the expression of specific miRNAs for DC proliferation and maturation like miR155 and miR221, were higher in the SQT (p<0.05). After 24 weeks, SQT restored significantly more circulating CD8Tcells (p=0.02), CD8+CD127+ Tcells (p=0.03) and reduced the PD-1 expression on CD8 T-cells (p=0.04) vs. TM. Our results show that in a short period of 24 weeks, SQT significantly improves functionality of DCs. Upregulation of TLR7 and TLR9 and miR155 in DCs by PEG-IFN-α is a novel mechanism that may be quite significant in mounting an effective antiviral response. Influence of longer duration of SQT and immunomodulation needs to be studied.
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical and Cellular Immunology.
Commentary · 22 Jul 2026
From Bench to Bedside: Reframing the CXCL13/CXCR5 Axis as a Non-Redundant Organizer of Protective Pulmonary Immunity in COVID-19
Commentary · 17 Jul 2026
CD5L:p40, a third wheel to IL-12 and IL-23 biology?
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical and Cellular Immunology
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Nirupma Trehanpati”
- BylineArticles whose byline prints “Arshi Khanam”
- BylineArticles whose byline prints “Syed Hissar”
- BylineArticles whose byline prints “Rashi Sehgal”
- BylineArticles whose byline prints “Ritu Khosla”
- BylineArticles whose byline prints “Paul David”
- BylineArticles whose byline prints “Ashish kumar”
- BylineArticles whose byline prints “Anupama Prashar”
